Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)

PHASE3CompletedINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Cancer of the PharynxCancer of the LarynxCancer of the Nasal CavityParanasal Sinus NeoplasmsCancer of the Oral Cavity
Interventions
DRUG

docetaxel

75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)

DRUG

cisplatin

75 mg/m2 on day 1

DRUG

hydroxyurea

Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)

DRUG

fluorouracil

750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)

PROCEDURE

chemotherapy

See protocol for details

PROCEDURE

radiotherapy

See protocol for details

Trial Locations (26)

10000

Clinic of Oncology, University Hospital Center Zagreb, Zagreb

University Hospital for Tumors Zagreb, Zagreb

19111

Fox Chase Cancer Center, Philadelphia

22000

Clinique Armoricaine de Radiologie, Saint-Brieuc

28040

Hospital Clínico San Carlos, Madrid

33136

UM Sylvester Comprehensive Cancer Center, Miami

38104

University of Tennessee Cancer Institute, Memphis

46815

Fort Wayne Medical Oncology/Hematology Inc., Fort Wayne

47807

AP&S Clinic, LLC, Terre Haute

48202

Henry Ford Health System, Detroit

49085

Oncology Care Associates PLLC, Saint Joseph

53215

Oncology Alliance, Milwaukee

55455

University of Minnesota, Minneapolis

58122

Roger Maris Cancer Center, Fargo

60201

Evanston Northwestern Healthcare, Evanston

60435

Joliet Oncology Hematology Associates, Joliet

60611

Northwestern University, Chicago

60612

Rush University Medical Center, Chicago

60637

The University of Chicago, Chicago

60640

Weiss Memorial Hospital, Chicago

64128

Kansas City VA Medical Center, Kansas City

66160

University of Kansas Cancer Center, Kansas City

78258

UT Health Science Center at San Antonio, San Antonio

90033

USC University of Southern California Keck School of Medicine, Los Angeles

Unknown

NN Blokhin Russian Cancer Research Centre RAMS, Moscow

Republican Oncology Dispensary, Ufa

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00117572 - Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) | Biotech Hunter | Biotech Hunter